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Abstract
Definition of the disease: Ataxia telangiectasia (A-T) is an autosomal recessive disorder primarily characterized by
cerebellar degeneration, telangiectasia, immunodeficiency, cancer susceptibility and radiation sensitivity. A-T is often
referred to as a genome instability or DNA damage response syndrome.
Epidemiology: The world-wide prevalence of A-T is estimated to be between 1 in 40,000 and 1 in 100,000 live
births.
Clinical description: A-T is a complex disorder with substantial variability in the severity of features between
affected individuals, and at different ages. Neurological symptoms most often first appear in early childhood when
children begin to sit or walk. They have immunological abnormalities including immunoglobulin and antibody
deficiencies and lymphopenia. People with A-T have an increased predisposition for cancers, particularly of
lymphoid origin. Pulmonary disease and problems with feeding, swallowing and nutrition are common, and there
also may be dermatological and endocrine manifestations.
Etiology: A-T is caused by mutations in the ATM (Ataxia Telangiectasia, Mutated) gene which encodes a protein of
the same name. The primary role of the ATM protein is coordination of cellular signaling pathways in response to
DNA double strand breaks, oxidative stress and other genotoxic stress.
Diagnosis: The diagnosis of A-T is usually suspected by the combination of neurologic clinical features (ataxia,
abnormal control of eye movement, and postural instability) with one or more of the following which may vary in
their appearance: telangiectasia, frequent sinopulmonary infections and specific laboratory abnormalities (e.g. IgA
deficiency, lymphopenia especially affecting T lymphocytes and increased alpha-fetoprotein levels). Because certain
neurological features may arise later, a diagnosis of A-T should be carefully considered for any ataxic child with an
otherwise elusive diagnosis. A diagnosis of A-T can be confirmed by the finding of an absence or deficiency of the
ATM protein or its kinase activity in cultured cell lines, and/or identification of the pathological mutations in the
ATM gene.
Differential diagnosis: There are several other neurologic and rare disorders that physicians must consider when
diagnosing A-T and that can be confused with A-T. Differentiation of these various disorders is often possible with
clinical features and selected laboratory tests, including gene sequencing.
Antenatal diagnosis: Antenatal diagnosis can be performed if the pathological ATM mutations in that family have
been identified in an affected child. In the absence of identifying mutations, antenatal diagnosis can be made by
haplotype analysis if an unambiguous diagnosis of the affected child has been made through clinical and
laboratory findings and/or ATM protein analysis.
Genetic counseling: Genetic counseling can help family members of a patient with A-T understand when genetic
testing for A-T is feasible, and how the test results should be interpreted.
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Management and prognosis: Treatment of the neurologic problems associated with A-T is symptomatic and
supportive, as there are no treatments known to slow or stop the neurodegeneration. However, other
manifestations of A-T, e.g. immunodeficiency, pulmonary disease, failure to thrive and diabetes can be treated
effectively.
Keywords: Cancer, Neurodegeneration, Cerebellum, Purkinje cells, Immunodeficiency, Dysphagia, Pulmonary
disease
Background
Ataxia telangiectasia, or A-T, is also referred to as Louis-
Bar Syndrome (OMIM #208900). Orphanet Orpha Num-
ber: ORPHA100. A-T was given its commonly used name
by Elena Boder and Robert P. Sedgwick, who in 1957 de-
scribed a familial syndrome of progressive cerebellar
ataxia, oculocutaneous telangiectasia and frequent pul-
monary infection [1].
Definition
A-T is an autosomal recessive cerebellar ataxia [2]. It has
also been widely referred to as a genome instability syn-
drome, a chromosomal instability syndrome, a DNA re-
pair disorder, a DNA damage response (DDR) syndrome
and, less commonly, as a neurocutaneous syndrome. A-T
is characterized by progressive cerebellar degeneration,
telangiectasia, immunodeficiency, recurrent sinopulmon-
ary infections, radiation sensitivity, premature aging, and a
predisposition to cancer development, especially of
lymphoid origin. Other abnormalities include poor
growth, gonadal atrophy, delayed pubertal development
and insulin resistant diabetes [3]. It is important to note
that A-T is a complex disease and not all people have the
same clinical presentation, constellation of symptoms
and/or laboratory findings (e.g. telangiectasia are not
present in all individuals with A-T, see Clinical Descrip-
tion below) [4].
Cells derived from patients with A-T demonstrate sen-
sitivity to ionizing irradiation, chromosomal instability,
shortened telomeres, premature senescence and a de-
fective response to DNA double strand breaks (DSBs)
(reviewed in [5] and [6] and more recently in [7]).
Epidemiology
With the exception of consanguineous populations, in-
dividuals of all races and ethnicities are affected equally
by A-T. The prevalence is estimated to be <1–9/
100,000, although incidences as high as 1 in 40,000 [8,
9] and as low as approximately 1 in 300,000 [9] have
been reported.
Clinical description
Because not all children develop in the same manner or
at the same rate, the diagnosis of A-T may not be made
until the early school years when the neurologic symp-
toms (impaired gait, hand incoordination, abnormal eye
movements), and the telangiectasia appear or become
worse. Different forms or presentations of A-T have been
described in the literature, with those more severe variably
categorized as “classic”, “typical”, “early onset” or “child-
hood onset” A-T, while milder forms have been referred
to as “variant”, “atypical”, “late onset” or “adult onset” A-
T. We utilize the terms “classic” and “mild” to distinguish
the two different, but broadly recognized, clinical presen-
tations of A-T. People with mild A-T present with less se-
vere, later onset manifestations associated with longer
survival (for a more detailed comparison of the classic and
mild clinical forms of A-T see Etiology: Genotype/Pheno-
type Correlations).
Ataxia and other neurological manifestations
In the classic presentation of the disease, ataxia first ap-
pears during the toddler stage when children begin to sit
and walk. Children with A-T often start walking at a nor-
mal age but then fail to improve much from their initial
wobbly gait (reviewed in [4, 10] and [11]). Often they have
problems standing or sitting still and tend to sway slowly
from side to side or backwards. Because most children
with classic A-T have stable neurologic symptoms for the
first 4–5 years of life, they initially may be labeled as hav-
ing “ataxic cerebral palsy” [10], but the existence of such a
syndrome is nosologically unclear.
In primary school years, walking becomes more difficult,
and children will use doorways and walls for support.
Children with A-T often run or walk quickly, and do so
with a curiously narrow stance, in deference to walking
more carefully and slowly. Around the beginning of their
second decade children with classic A-T start using a
wheelchair in the community setting [4]. During school
years children often have increasing difficulty with reading
because of impaired coordination of eye movement (see
“Eye and Vision” below). At the same time, other prob-
lems with fine motor functions (writing, coloring, and
using utensils to eat) and with dysarthria may arise
([4, 12]). Drooling may persist beyond expected ages
and particularly in young children when they are tired
or concentrating. Most of these neurologic problems
stop progressing after the age of about 12–15 years.
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At any age, however, individuals with A-T may develop
increasing difficulty with involuntary movements. These
can take many forms, including chorea, athetosis, dys-
tonia, myoclonic jerks, or various tremors including
rhythmic and non-rhythmic movements that complicate
intended movements [13, 14]. Other extrapyramidal
symptoms may include body hypokinesia or bradykinesia
and facial hypomimea ([4, 11]).
Distal to proximal advancing loss of tendon reflexes is
also characteristic of A-T [8], reflecting a progressive
sensory and motor neuropathy [4, 15].
Although many systemic complications can create a
complex clinical picture, the distinct pattern of neuro-
logical decline associated with the classic presentation of
A-T is depicted in Fig. 1.
Neuroimaging findings
The neuropathological hallmark of A-T is diffuse degen-
eration or atrophy of the cerebellar vermis and hemi-
spheres, involving Purkinje cells (PCs) and, to a lesser
extent, granule neurons. Various neuropathological ab-
normalities (e.g. neuronal changes, gliosis and vascular
changes) have also been observed in the cerebrum, brain
stem and spinal cord. (reviewed extensively in [10] and
more recently in [16]).
Although early neuroimaging studies in A-T were per-
formed using computed tomography (CT), for technical
reasons, and because of the requirement for radiation,
magnetic resonance imaging (MRI) is the preferred mo-
dality for visualizing the central nervous system (CNS)
and spinal cord in A-T. Studies utilizing T1- and T2-
weighted MRI and more recently diffusion MRI (dMRI)
have been published [16].
For the majority of people with A-T, neuroimaging
studies in the toddler years and early child years are nor-
mal ([11] and unpublished observations). As the disease
progresses, MRI studies support the pathological finding
of variable, progressive and diffuse cerebellar atrophy
[16]. Between patients it is notable that the magnitude
of volume loss correlates poorly with clinical features
(unpublished observations).
In addition to cerebellar atrophy, MRI studies have dem-
onstrated cerebral, white matter abnormalities in older pa-
tients, including hemosiderin deposits and deep cerebral
telangiectatic vessels, as well as degenerative changes in
white matter corticomotor tracts extending from the cere-
bellum in younger patients with A-T [17–19].
Magnetic resonance spectroscopy (MRS) studies to
measure the levels of various brain metabolites have also
been performed for A-T, although with somewhat con-
flicting results [20, 21]. Lin et al. found decreased levels
of all analyzed metabolites (N-acetyl aspartate [NAA],
choline [Cho], and creatine [Cr]) in the cerebellar vermis
with a trend towards decreased metabolite levels in the
cerebellar hemispheres [20], whereas Wallis et al. ob-
served increased levels of Cho in the cerebellum of
adults with A-T [21].
A positron emission tomography (PET) study to meas-
ure brain glucose metabolism in individuals with A-T
has also been performed [22]. Due to the radiation ex-
posure inherent in PET imaging, participants in this
study were restricted to 18 years of age or older. Al-
though glucose metabolism was uniformly reduced in
the cerebellum of patients with A-T, increased metabol-
ism observed in the globus pallidus was associated with
decreased motor performance. Additional imaging stud-
ies are warranted; however, these results suggest that
deep brain stimulation (DBS) targeting the pallidus may
be a therapeutic option for A-T [22].
Telangiectasia
Telangiectasia within the bulbar conjunctiva over the
exposed sclera of the eyes usually occur by the age of
5–8 years, but sometimes later or not at all (Fig. 2) [23].
Fig. 1 The Pattern of Neurologic Decline in Classic A-T [173]. * AT Scale Scores based on the Crawford Quantitative Neurologic A-T Scale
[174]; 100 = Normal
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The absence of telangiectasia does not exclude the diagno-
sis of A-T. Although potentially a cosmetic problem, the
ocular telangiectasia do not bleed or itch though they are
sometimes misdiagnosed due to chronic conjunctivitis or
allergy. It is their constant nature, not changing with time,
weather or emotion, which marks them as different from
other visible blood vessels. Telangiectasia can also appear
on sun-exposed areas of skin, especially the face and ears.
They occur in the bladder as a late complication of
chemotherapy with cyclophosphamide, have been seen
deep inside the brain of older people with A-T [17], and
occasionally arise in the liver and lungs (unpublished
observations).
Eye and vision
The telangiectasia do not effect vision and visual acuity
is normal in A-T [24]. However, control of eye move-
ment and visual fixation is often impaired affecting func-
tions that require fast, accurate eye movements from
point to point (e.g. reading). Abnormal eye movements
associated with A-T include: oculomotor apraxia, nys-
tagmus (including horizontal nystagmus in primary gaze,
nystagmus on lateral gaze, post-rotary nystagmus and
periodic alternating nystagmus), hypometric saccades
and saccadic intrusions, convergence/accommodation
and VOR abnormalities [25–27]. Strabismus is common.
There may be difficulty in coordinating eye position and
shaping the lens to see objects clearly at close distances.
Immunological manifestations
About two-thirds of people with A-T have abnormalities
of the immune system [28, 29]. The most common ab-
normalities are low levels of one or more classes of im-
munoglobulin (IgG, IgA, IgM or IgG subclasses), failure
to make antibodies in response to vaccines or infections,
and lymphopenia, especially affecting T-lymphocytes.
There are reduced numbers of new B cells leaving the
bone marrow and new T cells leaving the thymus [30],
reduced proportions of naive B and T cells, and reduced
antigen receptor repertoire [29]. A small percentage of
people with A-T also may have elevated levels of IgM in
combination with IgG and/or IgA deficiency. When this
is the presenting symptom in infant- or childhood, the
diagnosis of A-T can be confused with that of hyper-IgM
syndrome [31]. In the majority of individuals with A-T,
the immunologic abnormalities do not deteriorate over
time, but approximately 10% will develop more severe
problems most often with humoral immunity [28, 32].
Sinopulmonary infections are common in people with
A-T [28, 33, 34]. All children with A-T should have their
immune systems evaluated to detect those with severe
problems that require treatment to minimize the num-
ber or severity of infections.
People with A-T have an increased risk of developing
autoimmune or chronic inflammatory diseases. This risk
is probably a secondary effect of their immunodeficiency
and not a direct effect of the lack of ATM protein. The
most common examples of such disorders in A-T in-
clude immune thrombocytopenia (ITP), several forms of
arthritis, and vitiligo.
Fewer than 10% of people with A-T develop chronic
cutaneous granulomas that are thought to be due to dis-
ordered inflammation [35, 36].
Pulmonary manifestations
Chronic lung disease develops in more than 25% of
people with A-T [37]. Lingering cough, chest congestion
and/or wheeze may be early symptoms of underlying
lung disease in a person with A-T. These symptoms may
occur in the absence of other systemic symptoms, result-
ing in delayed treatment. If respiratory symptoms are ig-
nored, severe manifestations of lung disease can occur
which include bronchiectasis, recurrent pneumonia, lung
fibrosis and interstitial lung disease (ILD). Although not
always avoidable, some of these conditions can be pre-
vented by recognition of cause and early treatment [38].
Immune dysregulation in A-T can lead to recurrent
pneumonia, bronchiectasis and ILD. Poor mucociliary
clearance from an inadequate cough and chronic aspir-
ation from impaired bulbar function can increase sever-
ity of chronic respiratory symptoms.
Restrictive lung disease is common in A-T and is char-
acterized by lower than normal forced vital capacity
(FVC) [39, 40]. Low FVC and decreased pulmonary
reserve in people with A-T can increase their risk for
pulmonary complications from respiratory illnesses, sys-
temic stress and anesthetic procedures for surgery. Iden-
tifying those with restrictive lung disease can help
providers avoid respiratory complications during elective
and non-elective anesthesia and surgery [41]. Causes of
restrictive lung disease in A-T include respiratory
muscle weakness, impaired coordination of muscles
involved in respiration and ILD [42]. Shortened
Fig. 2 Ocular Telangiectasia in a Person with A-T
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telomeres and sensitivity to ionizing radiation are also
characteristic of A-T and can increase the risk of
complications such as pulmonary fibrosis when treat-
ing malignancies [43, 44].
Two studies have found an association between higher
systemic levels of the pro-inflammatory cytokines IL6
and IL8 and lower percent FVC in people with A-T sug-
gesting a link between inflammation and lung decline in
this disease [45, 46].
Cancer
People with A-T have a highly increased incidence (ap-
proximately 25% lifetime risk [47, 48]) of cancers.
Lymphomas and leukemias most often occur in people
with classic A-T less than 20 years of age, but adults are
susceptible to both lymphoid tumors and a variety of
solid tumors including breast, liver, gastric and esopha-
geal carcinomas (unpublished observations). An exten-
sive analysis of the types of cancers that occur in both
the classic and mild forms of the disease has been per-
formed on combined cohorts from the UK and the
Netherlands [47].
There is as yet no way to predict which individuals with
A-T will develop cancer, and unlike surveillance for many
solid tumors (e.g. mammography, colonoscopy, PSA
levels), there are no accepted methods to provide surveil-
lance for lymphomas and leukemias. Hematopoietic
cancer must be considered as a diagnostic possibility
whenever potential symptoms (e.g. persistent swollen
lymph nodes, unexplained fever) arise.
Cancer in A-T carriers
Carriers, those who have one mutated copy of the ATM
gene, such as the parents of a person with A-T, are gen-
erally healthy. However, a systematic meta-analysis
found that ATM mutation carriers have a reduced life-
span due to cancer (breast and gastrointestinal tract)
and ischemic heart disease [49].
In particular, ATM is considered a moderate risk or
moderate penetrance breast cancer susceptibility gene
[50, 51]. Female carriers are considered to have an ap-
proximately 2.3 fold increased risk for the development
of breast cancer compared to the general population
[51–53]. A 2016 meta-analysis found the cumulative risk
of breast cancer in carriers to be approximately 6% by
age 50 and approximately 30% by age 80 [54]. Standard
breast cancer surveillance, including monthly breast self-
exams and mammography at the usual schedule for age,
is recommended unless an individual has other risk fac-
tors (e.g., family history of breast cancer).
Radiation sensitivity
People with A-T have an increased sensitivity to ionizing
radiation (X-rays and gamma rays), which can be
cytotoxic. X-ray exposure should be limited to times
when it is medically necessary for diagnostic purposes.
Radiation therapy for cancer or any other reason is gen-
erally harmful for individuals with A-T and should be
performed only in rare circumstances and at reduced
doses [55, 56]. Although A-T cells in culture have an al-
tered DNA damage response to other genotoxic agents
(e.g. ultraviolet [UV] light) [57, 58], individuals with A-T
do not have an increased incidence of skin cancer and
can cope normally with sun exposure, so there is no
need for special precautions for exposure to sunlight.
Radiation sensitivity in carriers
Cultured cells from heterozygote carriers of ATM muta-
tions have been reported to have a variable but “inter-
mediate” sensitivity to radiation, being more sensitive
than normal control cells but less sensitive than homo-
zygous ATM null cells [59–61]. Clinically, a 1998 study
of heterozygotes in families with A-T demonstrated no
hypersensitivity to therapeutic radiation for carriers with
prostate and breast cancer [62]. Although one study
reported that women who possess specific rare patho-
logical ATM missense variants and who receive thera-
peutic radiation may have an elevated risk for developing
contralateral breast cancer [63], this precaution will not
apply to the majority of carriers who develop breast or
any other cancer. In our opinion, cancer therapy in A-T
carriers should be based on what is considered the current
and best curative option.
Feeding, swallowing, and nutrition
Feeding and swallowing (deglutition) may become difficult
for people with A-T as they age [64]. Primary goals for
feeding and swallowing are safe, adequate, and enjoyable
mealtimes. Involuntary movements can make self-feeding
difficult and result in messy or excessively prolonged
mealtimes. In general, meals longer than 30 min may be
stressful, interfere with other daily activities, and com-
promise hydration and nutritional intake.
Dysphagia is common in A-T and typically appears
during the second decade of life because of the neuro-
logical changes which interfere with the coordination of
mouth and pharynx movements necessary for safe and
efficient swallowing [64]. Coordination problems involv-
ing the mouth may make chewing difficult and increase
the duration of meals. Problems involving the pharynx
may cause aspiration of liquid, food, and saliva. Dyspha-
gia with concomitant silent aspiration may cause lung
problems because of impaired clearance of food or liq-
uids from the airway.
Dysphagia also can result in nutritional compromise
because the process of eating becomes slow and difficult.
Some people with A-T stop eating or reduce their intake
at meals because of frustration or fatigue with the
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process. Insufficient caloric intake may compromise
growth in children and weight maintenance in older per-
sons, contributing to lower body mass indices (BMI) in
comparison to healthy, age-matched individuals [65–69].
Poor nutrition may exaggerate the presentation of
neurologic disability. Abnormal respiratory-swallowing
coupling has been associated with an increased risk for
aspiration and may signify swallowing problems prior to
the development of nutritional and pulmonary sequelae
in A-T [70]. Warning signs of a problem with deglutition
are presented in Table 1.
Endocrine abnormalities
Poor growth Poor growth is a common feature of A-T.
Nutritional compromise, infections and altered growth
factor and hormone levels have been proposed to con-
tribute to this growth impairment [71, 72]. A study of
endocrine abnormalities in an Israeli cohort of patients
with A-T demonstrated that growth impairment was
present in infancy, prior to the onset of neurological
symptoms and the nutritional problems commonly seen
as children age. This study also showed that impaired
growth was more prominent in females than males, and
that this difference is apparent at an age before gonado-
tropins begin to affect growth rates [3].
Delayed pubertal development/gonadal dysgenesis
Infertility is often described as a facet of A-T. Whereas
this is certainly the case for the mouse models of A-T
[73–76], in humans it may be more accurate to describe
the reproductive abnormalities as gonadal atrophy or
dysgenesis causing delayed pubertal development and
early menopause. Abnormalities in gonadal development
and function appear to be more prominent in females
than males [3]. We are aware of pregnancies in people
with mild forms of A-T ([77] and unpublished observa-
tions), but not in anyone with the classic form of the
disease.
Insulin-resistant diabetes A minority of patients with
A-T suffer from insulin resistant diabetes which typically
appears as a late event during disease progression. Of
note, reduced insulin sensitivity and dysglycemia may be
observed in individuals with A-T who do not have
diabetes [78].
Hair and skin
A-T can cause features of early aging such as premature
graying of the hair [4]. People with A-T can also have an
increased prevalence of vitiligo, and warts that can be
extensive and recalcitrant to treatment ([28] and unpub-
lished observations).
Sleep
Interestingly, unlike other neuromotor disorders, such as
Duchenne Muscular Dystrophy, overnight polysomno-
graphy has not identified regular sleep-related gas ex-
change abnormalities in patients with A-T. The majority
of subjects studied were noted to have decreased sleep
efficiency which has been associated with chronic dis-
ease states [79].
Cognition
Very few neuropsychological studies have been per-
formed in individuals with A-T. One study performed in
2000 demonstrated deficits in the judgement of duration
(i.e. the “judgement of explicit time intervals” or percep-
tual timing) [80].
Subsequent studies demonstrated that certain cogni-
tive deficits appear relatively early in A-T, then be-
come broader and more profound during later stages
of the disease [81, 82]. In these studies specific im-
pairments were observed in intellectual functioning,
nonverbal memory, verbal abstract reasoning and cal-
culation, and executive function. Pronounced deficits
in perceptual timing were also observed; however
language functioning was not impaired and “expres-
sive language” was noted as a strength in children
with A-T, even during later stages of the disease. The
cognitive impairments seen in A-T have been found
to be characteristic of Cerebellar Cognitive Affective
Syndrome (CCAS) [83, 84].
Orthopedic manifestations
Acquired deformity of the feet is common in people
with A-T (unpublished observations) and compounds
the difficulty individuals have with walking due to im-
paired coordination. Scoliosis also occurs ([85] and un-
published observations), but is relatively uncommon.
Occasionally, individuals with A-T develop contractures
of the fingers, most often because of inflammatory con-
nective tissue disease, but sometimes from neuropathy.
Table 1 Warning Signs of a Swallowing Problem in A-T
• Choking or coughing when eating or drinking
• Poor weight gain during ages of expected growth or weight loss at
any age
• Excessive drooling
• Mealtimes longer than 40–45 min, on a regular basis
• Foods or drinks previously enjoyed are now refused or difficult
• Chewing problems
• Increase in the frequency or duration of breathing or respiratory
problems
• Increase in lung infections
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Manifestations in aging or older patients with A-T
Certain problems occur with an unexpectedly high fre-
quency in patients with A-T who survive into their
twenties and beyond. Table 2 provides a list of these
types of problems.
Of particular note, liver abnormalities, such as elevated
serum transaminase levels, steatosis and non-alcoholic
cirrhosis including fibrotic changes have been observed
as people with A-T age, as have elevated triglyceride and
cholesterol levels [3, 86, 87].
The spectrum of malignant disease is also different in
older individuals with classic A-T, as there is an in-
creased risk for the development of both lymphoid
malignancies and solid tumors in people over the age of
20 (unpublished observations).
Other manifestations of A-T
Some people with A-T suffer from bladder and/or
bowel incontinence that results from difficulties with
transfers rather than a length-dependent neuropathy.
Some individuals also go through a period of recur-
rent vomiting which appears to be more prevalent in
the mornings. This transient but repeated vomiting
may correlate with the development of eye movement
abnormalities, as people can have a sensation of
motion sickness or dizziness with head movement.
This symptom can be treated with drugs for motion
sickness and usually resolves in a period of months,
possibly as the eye movement abnormalities become
more severe. ([88] and unpublished observations).
Etiology
Genetics
The mode of inheritance for A-T is autosomal recessive.
A-T is caused by mutations in the ATM (ataxia telangi-
ectasia, mutated) gene which was cloned by Savitsky et al.
in 1995 [89]. ATM is located on human chromosome
11q22-q23 [90] and is made up of 66 exons (four non-
coding and 62 coding) spanning 150 kb of genomic DNA.
Genotype / phenotype correlations
The ATM gene is large, and although certain populations
contain a higher frequency of identical mutations due to
the founder effect [91, 92], there is no one area of the
gene especially susceptible to mutation. Mutations have
been identified in the proximal, central and distal re-
gions of the human ATM gene [92]. These include pri-
marily nonsense mutations and frame shifts resulting
from insertions and deletions, but also missense and
leaky splice-site mutations. Compound heterozygosity is
common [93].
In 1998, a genotype/phenotype analysis was performed
on a small cohort of individuals who had less severe clin-
ical presentations of A-T [94]. Subsequently, other ana-
lyses of genotype/phenotype correlations in disease
severity and in the development of cancer were performed
on larger A-T cohorts ([47, 95, 96] and reviewed in [97]).
Briefly, the majority of ATM mutations are truncating
[98, 99], creating highly unstable protein fragments. In
such cases, ATM protein cannot be detected by western
blotting and ATM kinase activity is not observed. Indi-
viduals who possess these mutations have a classic clin-
ical presentation of A-T, and the severity of their disease
follows a relatively predictable course (see Fig. 1 and
Table 3). Individuals with A-T possessing residual ATM
protein (observable by western blot) that lacks kinase ac-
tivity also may present with this classic phenotype [95].
Certain missense mutations, in-frame mutations or
leaky splice-site mutations allow for the production of
residual amounts of functioning ATM protein [97].
ATM protein can be detected on western blots and some
level of kinase activity is present. Individuals who pos-
sess these types of ATM mutations have traditionally
been referred to as “atypical” or “variant,” and more re-
cently as “mild.” Because there is some degree of re-
sidual ATM function, from either normal or mutant
protein, the overall severity of their clinical course is
less, and the progression of their disease is slower
(Table 3). Of note, in the mild form of the disease, the
diagnosis of cancer can precede the diagnosis of A-T
[100, 101]. As radiation therapy and radiomimetic
chemotherapy can be especially cytotoxic in individuals
with this disease, a diagnosis of A-T should be consid-
ered for any individual with cancer who has an undiag-
nosed disorder associated with gait disturbance or eye
Table 2 Problems Observed in Aging or Older People
with A-T
• Ballistic, retropulsive or jerky movements
• Sensory and motor neuropathy
• Brain telangiectasia (observed by MRI)
• Restrictive lung disease
• Elevated cholesterol and triglyceride levels
• Glucose intolerance and diabetes
• Liver abnormalities (e.g. fatty liver; non-alcoholic cirrhosis; elevated
serum transaminases)
• Changes in the types of malignancies (there is an increased
incidence for both lymphoid and solid tumors)
• Osteoporosis/osteopenia and low vitamin D levels
• Postural scoliosis and progressive foot deformities




• Aging parents and caregivers
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movement abnormality, especially if the symptoms are
progressive.
Mild cases also have been reported to present with
neurological symptoms in adulthood versus childhood
[95, 102–105]; however, in at least one case report
the authors could not definitively rule out the possi-
bility that mild neurological abnormalities existed in
childhood [102].
Interestingly, three documented “null” milds have been
reported in the literature [77, 106]. The neurological
presentation and progression of their disease is mild.
However, these patients have null ATM mutations
(frameshift and splice site mutations causing truncation),
no ATM protein detectable by western blot analysis, no
kinase activity and the typical cellular phenotype for
classic A-T. Therefore, these individuals somehow com-
pensate for the absence of functioning ATM protein. Al-
though rare, these patients are of particular interest
because the genetic and/or environmental factors that
modify the severity of their clinical course may represent
targets for treatment interventions.
Other A-T “variants” were described earlier in 1992
[107]. These individuals possessed a classic clinical pres-
entation but an intermediate cellular radiosensitivity
phenotype. Given that some individuals, albeit rare, can
present with a mild disease course but classic cellular
radiosensitivity, it appears that clinical severity does not
always correlate with the in vitro radiation sensitivity of
cultured cells.
Pathophysiology: how does loss of the ATM protein create
a multisystem disorder?
The ATM gene encodes a large 3056 amino acid protein
of the same name whose best known, and arguably most
well understood, role is coordinating the cellular re-
sponse to DNA DSBs. However, the ATM kinase also re-
sponds to oxidative stress, other forms of genotoxic
stress and other stressors that affect cellular homeosta-
sis, resulting in the direct phosphorylation and regula-
tion of an ever-growing list of downstream substrates
([108, 109] and reviewed in [110]). A summary of the
features of the ATM protein is presented in Table 4.
Cancer In the absence of the ATM protein, the signaling
network that responds to DNA DSBs is defective, and
responses to other types of genotoxic stress are reduced
to various degrees. The result is genomic instability
which can lead to the development of cancers [6].
Radiosensitivity Irradiation (e.g. radiation therapy for
cancers) and radiomimetic compounds (e.g. those used
in cancer chemotherapy protocols) induce DSBs and
other DNA lesions whose repair is severely impaired
when ATM is absent. Consequently, such agents can
prove especially cytotoxic to people with A-T.
Table 3 Classic vs. Mild Forms of A-T
Classic Form Mild Form
Neurological
Manifestations
Neurological deficits are typically observed during
the toddler years resulting in wheelchair
dependency around the age of 10.
Individuals have more mild neurological deficits in
childhood with slower age-related neurodegeneration.
The predominant neurological symptoms or symptoms
to present first may be myoclonus, dystonia,
choreoathetosis or tremor with ataxia appearing
later [175–177]. Oculomotor apraxia may also appear
later or not at all [95].
Immunodeficiencies Roughly two-thirds of people with classic A-T
suffer from some type of immunodeficiency
and/or lymphopenia.
Immunodeficiencies do occur, but are less common.
Pulmonary Disease Relatively common. Less common.
Cancer Although malignancies in these individuals tend
to occur at a younger age and are often lymphoid
in nature, cancers in older individuals do occur
and include both hematopoietic and
non-hematopoietic malignancies.
Malignancies tend to appear later in life and include a
higher proportion of non-hematopoietic cancers.
The diagnosis of cancer can precede the diagnosis
of A-T.
Table 4 The ATM Protein (reviewed in [110])
• 3056 amino acids
• Serine/Threonine protein kinase
• Member of the family of PI3 Kinase-like Kinases (PIKKs)
• Located primarily in the nucleus; smaller amounts in the cytoplasm
and associated with mitochondria and peroxisomes [178]
• Activated primarily by DSBs and oxidative stress, but also agents
affecting chromatin organization, hypoxia, hypotonic stress and
hyperthermia
• Phosphorylates and regulates a variety of protein substrates
involved in
o The DNA damage response (NHEJ and HRR) to DSBs
o Various other genotoxic stress responses
o DNA repair processes
o Cell cycle checkpoints
o Other cell stress responses
o Apoptosis
NHEJ non-homologous end-joining, HRR homologous recombination repair
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Immune system defects and immune-related cancers
As lymphocytes develop they undergo gene rearrange-
ments to generate clonal diversity and class switch
recombination, processes which generate DSBs. In the
absence of ATM, the effective repair of these DSBs is
difficult [111–113]. As a result many people with A-T
have reduced numbers of lymphocytes and some impair-
ment of lymphocyte function (such as an impaired
ability to make antibodies in response to vaccines or in-
fections) [28, 29]. In addition, chromosomal transloca-
tions can occur as a result of aberrant DSB repair,
making these cells prone to the development of cancer
(lymphomas and leukemias) [114, 115] (see Table 5).
Interestingly, treatment of Atm deficient mice with an-
tioxidants such as tempol, N-acetyl cysteine (NAC) or
the nitroxide antioxidant CTMIO delays the onset of
thymic lymphoma [116–118], suggesting that oxidative
stress characterized by elevated ROS and/or abnormal
redox signaling plays some role in lymphomagenesis in
these animals and perhaps humans.
Neurodegeneration A-T is one of several DNA repair
disorders which results in neurological abnormalities
and/or neurodegeneration (reviewed in [119–121]). Ar-
guably some of the most devastating symptoms of A-T
are a result of progressive cerebellar degeneration, char-
acterized by the gradual loss and/or aberrant location of
PCs and, to a lesser extent, the gradual loss of granule
cells [122, 123]. The cause of this cell death is not
known, though many hypotheses have been proposed
(reviewed in [11]). Current hypotheses to explain the
neurodegeneration associated with A-T are summarized
in Table 6. Much of the evidence in existence to date
supports the idea that a defective response to genotoxic
and/or oxidative stress contributes to the neuronal cell
dysfunction and death in A-T. However, the hypotheses
in Table 6 may not be mutually exclusive and more than
one of these mechanisms may underlie neuronal cell
death when there is an absence or deficiency of ATM.
Importantly, the loss of cerebellar cells does not ex-
plain all of the neurologic abnormalities seen in people
with A-T, and the effects of ATM deficiency on the
other areas of the brain outside of the cerebellum are
being actively investigated.
Pulmonary disease In addition to the neurological deficits
which contribute to bulbar weakness and the immunodefi-
ciencies which can contribute to susceptibility to chronic
sinopulmonary infections, several other factors may influ-
ence the development of pulmonary disease in A-T. These
include premature aging, inflammation, oxidative stress and
an inability to properly repair damage that occurs in the
lungs over time [124, 125]. Telomere shortening is also a
feature of A-T and has been found to be associated with
both idiopathic and genetically based ILDs [126].
Gonadal dysgenesis Because programmed DSBs are
generated to initiate meiosis, meiotic defects and arrest
can occur when ATM is not present ([127] and reviewed
in [5]) and may contribute to the gonadal dysgenesis as-
sociated with A-T.
Progeric changes Cells from people with A-T demon-
strate genomic instability, slow growth and premature
senescence in culture, shortened telomeres and an on-
going, low level genotoxic stress response [128–130].
These factors may contribute to the progeric changes of
skin and hair sometimes observed in people with A-T.
For example, DNA damage and genomic instability
cause melanocyte stem cell (MSC) differentiation which
Table 5 ATM and the Immune System
ATM is involved in:
o V(D)J recombination in the production of immunoglobulins and
α/β chain recombination in the production of T cell receptors [111, 112]
o Class switch recombination in B cells [179, 180]
o T cell proliferation and survival following T cell receptor stimulation
[181, 182]
ATM deficiency results in:
o Low immunoglobulin levels (particularly IgA, IgG subclasses and IgE)
o Lymphopenia (particularly affecting T cell numbers)
o Decreased immune repertoire diversity
o Genomic instability and translocations which can result in lymphoid
malignancies
Table 6 Hypotheses to Explain the Neurodegeneration in A-T
• Defective DDR [183, 184] or repair resulting in:
o the failed clearance of genomically damaged neurons during
development [76, 185]
o transcription stress [119] and abortive transcription involving
topoisomerase 1 cleavage complex (TOP1cc) dependent lesions
[186–189]
o aneuploidy [190]
• Defective response to oxidative stress characterized by elevated ROS
and altered cellular redox status
[191–194] and reviewed in [11, 195, 196]
• Mitochondrial dysfunction [197–199] and reviewed in [11]
• Defects in neuronal function involving:
o Failed cell cycle regulation resulting in the re-entry of post-mitotic
(mature) neurons into the cell cycle [200]
o Synaptic/vesicular dysregulation [201–203]
o Altered epigenetics including
− HDAC4 nuclear translocation [204]
− Histone H3 hypermethylation [205] and
− Reduced 5-hydroxymethylcytosine [206]
• Defects in brain vasculature [207]
• Altered protein turnover [208]
DDR DNA damage response
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produces graying. Thus, ATM may act as a “stemness
checkpoint” protecting against MSC differentiation and
premature graying of the hair [131]. An extensive review
of this aspect of A-T, including the various biochemical
pathways underlying it, has been performed [132].
Insulin-resistant diabetes The finding that insulin
signaling induces ATM-dependent phosphorylation of
4E-BP1 was published in 2000 [133]. Since that time,
others have demonstrated that the insulin and insulin-
like growth factor 1 (IGF-1) / IGF-1 receptor axes are af-
fected by the loss of ATM in cell models, Atm−/− mice
and in patients with A-T (recently reviewed in [134] and
[135]). Further, the loss of Atm protein in ApoE−/− mice
increases insulin resistance and exacerbates other fea-
tures of metabolic syndrome [136]. Therefore, the role
of ATM in insulin and IGF-1 metabolic signaling may
explain the diabetic phenotype sometimes seen in A-T.
Increased alpha-fetoprotein (AFP) levels AFP levels
are very high in all newborns, and normally descend to
adult levels over the first year to 18 months. Approxi-
mately 95% of people with A-T have elevated serum
AFP levels after the age of two, and measured levels of
AFP appear to increase slowly over time [137]. Why the
majority of individuals with A-T have elevated levels of
AFP remains unknown.
Appearance of telangiectasia The cause of telangiecta-
sia or dilated, enlarged blood vessels in the absence of
the ATM protein is not yet known.
Diagnosis
Because A-T is so rare, doctors may not be familiar with
the symptoms or criteria for making a diagnosis. The
late appearance of telangiectasia may also be a barrier to
diagnosis.
A diagnosis of A-T can usually be made by the com-
bination of clinical features and specific laboratory ab-
normalities. A variety of abnormal laboratory findings
occur in most people with A-T, but not all abnormalities
are seen in all patients. These abnormalities are listed in
Table 7.
The diagnosis of A-T can be confirmed by the absence
or deficiency of ATM protein and/or ATM kinase activ-
ity in cultured cell lines established from lymphocytes or
skin biopsies [138, 139] or the identification of patho-
logical mutations in the ATM gene. These more special-
ized tests are not always needed, but are particularly
helpful if an individual’s symptoms are atypical.
As whole exome sequencing becomes standard clinical
practice for individuals with unusual and/or unexplained
symptoms, it is likely that more people with mild forms
of A-T will be diagnosed ([140] and unpublished obser-
vations). This will necessarily change our views about
the phenotypic expression of A-T.
Differential diagnosis
There are several other disorders with similar symptoms
or laboratory features that physicians may consider when
diagnosing A-T [2]. The three most common disorders
that are sometimes confused with A-T are: cerebral
palsy, congenital ocular motor apraxia and Friedreich’s
ataxia. Each of these can be distinguished from A-T by
the neurologic exam and clinical history (unpublished
observations).
Cerebral palsy (CP)
CP describes any non-progressive disorder of motor func-
tion stemming from malformation or early damage to the
brain [141]. Because most children suffering from A-T
have stable neurologic symptoms for the first 4–5 years of
life, a misdiagnosis of cerebral palsy is not uncommon
[10]. However, milestones that have been accomplished
and neurologic functions that have developed do not de-
teriorate in CP as they often do in children with A-T in
the late pre-school years. In addition, most children with
CP manifest regional or diffuse spasticity in a pattern not
seen in A-T.
Those rare individuals that manifest a static disorder
characterized by predominantly cerebellar features have
been labeled as having “ataxic CP” (a term of uncertain
nosology). Most individuals in this group do not begin
walking at a normal age; however most children with A-
T do, although they often “wobble” from the start.
Children with ataxia caused by CP will not manifest the
laboratory abnormalities associated with A-T.
Congenital ocular motor apraxia
Congenital ocular motor apraxia (COMA; Cogan OMA)
is a rare disorder of delayed development of visual sac-
cades [142]. COMA arises early and improves with time,
whereas in A-T similar saccadic difficulties worsen over
time, typically in early school years.
Table 7 Laboratory Abnormalities in A-T
• Elevated and slowly increasing serum alpha-fetoprotein levels after two
years of age
• Low serum levels of immunoglobulins (IgA, IgG, IgG subclasses, IgE)
and lymphopenia (particularly affecting T-lymphocytes)
• Spontaneous and X-ray induced chromosomal breaks and rearrangements
in cultured lymphocytes and fibroblasts
• Reduced survival of cultured lymphocytes and fibroblasts after
exposure to ionizing radiation [209]
• Cerebellar atrophy detected by MRI
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Friedreich’s Ataxia (FA or FRDA)
FRDA is the most common genetic cause of ataxia in
children and the most prevalent autosomal recessive
cerebellar ataxia [2]. In FRDA, ataxia typically appears
between 10 and 15 years of age, and differs from A-T by
the absence of telangiectasia and oculomotor apraxia,
the early absence of tendon reflexes, a normal AFP, the
frequent presence of scoliosis, and abnormal features on
the EKG. FRDA and A-T also differ with regards to pro-
prioception. Individuals with FRDA manifest difficulty
standing in one place that is much enhanced by closure
of the eyes (positive Romberg sign). This is not charac-
teristic of A-T, even though those with A-T may have
greater difficulty standing in one place with their eyes
open ([10] and unpublished observations).
There are also other rare disorders that can be con-
fused with A-T, either because of similar clinical fea-
tures, a similarity of some laboratory features, or both.
These include: ataxia oculomotor apraxia type 1
(AOA1), ataxia oculomotor apraxia type 2 (AOA2, also
known as SCAR1), ataxia telangiectasia like disorder
(ATLD) and Nijmegen breakage syndrome (NBS). A
comparison of the clinical and laboratory features of
these disorders can be found in Table 8.
Differentiation of these disorders is often possible with
clinical features and selected laboratory tests. In cases
where the distinction is unclear, DNA sequencing and/
or protein assays (e.g. western blots or kinase assays to
detect abnormal protein levels or activity) can be used to
help make a definitive diagnosis.
Pre-implantation genetic diagnosis, antenatal diagnosis
and carrier identification
Pre-implantation genetic diagnosis (PGD) can avoid the
birth of an affected child. PGD has been performed
successfully for parents who have an affected child (or
children) with A-T, and at least two case reports appear
in the literature [143, 144].
Antenatal diagnosis and carrier detection can be cost
effectively performed in families if the ATM mutations
in an affected child have been identified. Antenatal diag-
nosis can also be performed using haplotype analysis if
an unambiguous diagnosis has been made for the af-
fected child. In this case, DNA polymorphisms within
and around the ATM gene can be utilized even if the
pathogenic mutations are not known.
Carrier testing in the general population, i.e. attempt-
ing to identify disease causing mutations in the ATM
gene of an unrelated individual (for example, the spouse
of a known A-T carrier), presents significant challenges.
The ATM gene is extremely large and often contains
polymorphisms which do not affect protein function.
Clinicians cannot always predict if a specific variant will
or will not cause disease.
Newborn screening for SCID can detect A-T
The newborn screening test for severe combined im-
munodeficiency (SCID) detects T cell receptor and B cell
kappa-deleting recombination excision circles (TRECs
and KRECs), characteristic of lymphocyte deficiency,
from infant dried blood spots. Other disorders charac-
terized by a deficiency or absence of T and B cells can
also be detected using this test [145]. Infants with T cell
lymphopenia and A-T have been diagnosed with the
SCID newborn screening test in combination with ex-
ome sequencing [146]. Although there is currently no
disease modifying therapy or cure for A-T, diagnosis in
infanthood allows for early family education and genetic
counseling (see below) as well as early and more aggres-
sive supportive care.
Genetic counseling
Genetic counseling can provide education for families
regarding the feasibility and potential consequences of
genetic testing for A-T in siblings and other family
members. Genetic counseling can also help with the in-
terpretation of test results.
Table 8 Clinical and Laboratory Features Of Rare Genetic Disorders that can be Confused With A-T (reviewed in [210] and [14])
A-T AOA1 AOA2 ATLD NBS
Human gene ATM APTX SETX MRE11 NBS1










Immune deficiency Yes No No Mild [211] Yes
Neurodegeneration Yes Yes Yes Yes No
Early Neurodevelopment Usually Normal Normal Normal Normal Microcephaly &
Cognitive Impairment
Cancer risk Yes No No Unknown Yes
Albumin Normal Low Normal Normal Normal
AFP High Normal High Normal Normal
DSB double strand break, SSB single strand break
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Management
The management and treatment of A-T is symptomatic
and supportive. Because A-T is a complex disease not all
patients suffer from the same constellation of symptoms
and they may vary in terms of the rate of disease pro-
gression and the on-set of complications. A brief review
of treatments used for the various manifestations of A-T,
as well as potential therapies including antioxidant and
mutation-targeted approaches has been performed [147].
Neurologic problems
There is no treatment known to slow or stop the
progression of the neurologic deficits associated with
A-T. Physical, occupational and speech therapies as
well as exercise may help maintain function but will
not slow the course of neurodegeneration. Thera-
peutic exercises should not be used to the point of
fatigue and should not interfere with activities of daily
life.
Certain anti-Parkinson and anti-epileptic drugs may be
useful in the management of symptoms. Commonly
prescribed drugs include trihexyphenidyl (Artane),
amantadine [148], baclofen and BOTOX® injections. Less
commonly prescribed drugs that also may be beneficial
include clonazepam [149], gabapentin and pregabalin
(Lyrica) (reviewed in [11]). Various pharmaceutical inter-
ventions, (e.g. Riluzole [150]), have shown improvement
in other cerebellar disorders. However, to date, their
efficacy and the features of motor impairment that
would best be targeted in A-T are not known. All drugs
should be prescribed by a neurologist familiar with the
assessment and treatment of individuals with movement
disorders.
Immune problems
All individuals with A-T should have at least one com-
prehensive immunologic evaluation that measures the
number and type of lymphocytes in the blood (T-lym-
phocytes and B-lymphocytes), the levels of serum immu-
noglobulins (IgG, IgA, and IgM) and antibody responses
to T-dependent (e.g., tetanus, Hemophilus influenzae b)
and T-independent (23-valent pneumococcal polysac-
charide) vaccines. For the most part, the pattern of
immunodeficiency seen in an A-T patient early in life
(by age five) will be the same pattern seen throughout
the lifetime of that individual [28, 32]; therefore, tests of
immune function need not be repeated unless that indi-
vidual develops more problems with infection. If infec-
tions are occurring in the lung, it is also important to
investigate the possibility of dysfunctional swallow with
aspiration.
Antibody deficiency Problems with immunity can some-
times be overcome by immunization. Vaccines against
common bacterial respiratory pathogens such as Hemo-
philus influenzae, pneumococci and influenza viruses are
commercially available and often help to boost antibody
responses, even in individuals with low immunoglobulin
levels. If the individual continues to have problems with
infections, gamma globulin therapy (IV or subcutaneous
infusions) may be of benefit. The need for additional im-
munizations (especially with pneumococcal and influenza
vaccines), antibiotics to provide prophylaxis from infec-
tions, and/or gamma globulin therapy should be deter-
mined by an expert in the field of immunodeficiency or
infectious diseases.
In people with A-T who have low levels of IgA, further
testing should be performed to determine if the IgA level
is low or completely absent. If IgA is absent, there is a
slight, albeit debatable, increase in the risk for a transfu-
sion reaction. “Medical Alert” bracelets are not neces-
sary, but the family and primary physician should be
aware that if there is an elective surgery requiring red
cell transfusion, the cells should be washed to decrease
the risk of an allergic reaction.
Gammopathy/elevated immunoglobulin levels A
small number of people with A-T develop an abnormal-
ity in which one or more types of immunoglobulin are
increased far beyond the normal range. In a few cases,
the immunoglobulin levels can be increased so much
that it causes hyperviscosity [151]. Therapy for this
problem must be tailored to the specific abnormality
found and its severity.
Lymphopenia Many people with A-T have low lympho-
cyte counts in the blood. This problem seems to be rela-
tively stable with age, but seldom causes susceptibility to
opportunistic infections. The one exception is that prob-
lems with chronic or recurrent warts and molluscum
contagiosum are relatively common [28].
The number and function of T-lymphocytes should be
re-evaluated if a person with A-T is treated with cortico-
steroid drugs such as prednisone for longer than a few
weeks or is treated with chemotherapy for cancer. If
lymphocyte counts are low in people taking those types
of drugs, the use of prophylactic antibiotics is recom-
mended to prevent opportunistic infections.
Normal antibody function and vaccination If antibody
function is normal, all routine childhood immunizations
including live viral vaccines (measles, mumps, rubella
and varicella) should be given. Recommended vaccines
for individuals with A-T are listed in Table 9.
Cutaneous granulomas Chronic cutaneous granulomas
occur in less than 10% of people with A-T. These lesions
have not been associated with an identifiable pathogen
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or other etiology [36], but can on occasion be painful,
bleed, or erode down to muscle or bone. Treatments
have included high potency topical corticosteroids and/
or cyclosporine A for small superficial lesions. More ex-
tensive granulomas may respond to combination therapy
(e.g. topical steroids plus IV gamma globulin therapy)
[152], systemic inhibitors of tumor necrosis factor
(TNF-alpha) [153] or direct injection of steroids into the
site of the granulomatous lesions [154].
Pulmonary problems
Recognizing and treating causes of chronic lung disease
can minimize morbidity and delay onset of respiratory
symptoms (reviewed in [124]). To slow or prevent the
development of chronic lung disease in A-T, early inter-
vention for respiratory symptoms is recommended. Pul-
monary function testing should be performed in all
children starting at 6 years of age and continued on an
annual basis. Although pulmonary function tests can be
difficult to perform in this population due to bulbar
weakness and delayed initiation of inspiratory breaths,
studies have demonstrated that with adjustments to the
technique, reproducible spirometry can be performed in
most people with A-T [39, 40, 124].
In people with chronic or persistent respiratory symp-
toms unresponsive to therapy, consideration should be
given to lung imaging to diagnose unsuspected bronchi-
ectasis, fibrosis, interstitial lung disease and tumors of
the chest. Low dose chest and sinus CT are currently
available which can minimize exposure to ionizing radi-
ation [124]. Alternatively, magnetic resonance imaging
can be used in people with A-T to identify lung abnor-
malities [155]. However, use of MRI may require
anesthesia in younger patients.
General considerations for infection management
Liberal use of antibiotics should be considered in people
with A-T who have persistent upper and lower respiratory
tract symptoms. As with cystic fibrosis, people with A-T
who are colonized with or who intermittently grow bac-
teria from their respiratory secretions are more likely to
develop bronchiectasis and have more frequent respira-
tory exacerbations triggered by respiratory viral illnesses.
Administration of antibiotics should be considered
when children and adults have prolonged respiratory
symptoms (greater than 7 days) following a respiratory
illness, including those that begin with a viral illness.
Antibiotic treatment also should be considered in chil-
dren with chronic coughs that are productive of mucus,
those who do not respond to aggressive pulmonary clear-
ance techniques and in children with muco-purulent
secretions from the sinuses or chest. Examination of re-
spiratory secretions by induced sputum or bronchoscopy
may direct antibiotic therapy to treat lower respiratory
tract infections and prevent the development of
bronchiectasis.
In individuals who have recurrent pneumonias, bron-
chiectasis, or low lung function the use of macrolides,
inhaled aminoglycoside and/or fluoroquinolones can
sometimes reduce exacerbations [156, 157] and slow
chronic lung disease progression. People with A-T and
ILD may be responsive to corticosteroids. In a retro-
spective study, ILD progression was attenuated with
early use of systemic corticosteroids [42]. However, this
has not been validated in a prospective study. Finally
people with restrictive lung disease associated with A-T
may also have a component of obstructive lung disease
responsive to bronchodilators [158].
Clearance of oral and bronchial secretions Clearance
of bronchial secretions is essential for good pulmonary
health and can help limit injury from acute and chronic
lung infections [159]. For those individuals with A-T
who have difficulty clearing oral and bronchial secre-
tions, techniques that allow clearance of mucus can be
helpful during respiratory illnesses; however, evaluation
by a pulmonary specialist should first be performed to
properly assess patient suitability.
Children and adults with increased bronchial secre-
tions may benefit from routine chest therapy using the
manual method, and a cappella device or a chest physio-
therapy vest. Chest physiotherapy can help bring up
mucus from the lower bronchial tree; however an ad-
equate cough is needed to remove secretions. In people
who have decreased lung reserve and a weak cough, use
of an insufflator-exsufflator device may be useful as a
maintenance therapy or during acute respiratory ill-
nesses to help remove bronchial secretions from the
upper airways.
Respiratory muscle strength A small study of 11 indi-
viduals with A-T found that inspiratory muscle training
Table 9 Vaccine Recommendations for A-T
• If a person with A-T does not need gamma globulin replacement
therapy, he/she should receive all standard childhood vaccines, including
the live vaccines for measles, mumps, rubella and varicella-zoster viruses.
• The individual with A-T and all household members should receive the
influenza (flu) vaccine every fall.
• People with A-T who are less than two years old should receive three
doses of a pneumococcal conjugate vaccine (Prevnar) given at two
month intervals.
• People older than two years who have not previously been
immunized with Prevnar should receive two doses of Prevnar.
• At least 6 months after the last Prevnar has been given, and after the
child is at least two years old, the 23-valent pneumococcal vaccine
should be administered. Immunization with the 23-valent pneumococcal
vaccine should be repeated approximately every five years after the first
dose.
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could improve respiratory muscle strength and quality of
life for people with A-T [160].
ERS international statement on the respiratory treat-
ment of A-T In November 2015, an international, multi-
disciplinary task force of the European Respiratory Society
(ERS) published a “Statement on the multidisciplinary re-
spiratory management of ataxia-telangiectasia” [38]. The
statement reviews the published data on lung disease in
A-T and makes recommendations for treatment.
Problems with anesthesia: peri- and post-operative risks
If possible, all people with A-T should have an anesthesia
or pulmonary consult before undergoing any surgical
procedure or study that requires anesthesia. In a small
retrospective study of people with A-T who underwent
anesthesia at a tertiary care center, few complications
were noted. However, they found that 24% of patients
required supplemental oxygen post anesthesia and that
44% had mild hypothermia [41]. People with a history of
significant restrictive lung disease may require non-
invasive ventilation (NIV) during the recovery period.
When possible, all procedures requiring anesthesia should
be performed at a tertiary care center that has surgical
and anesthetic expertise in the care of individuals with
chronic respiratory and neuromuscular disease.
Problems with feeding, swallowing and nutrition
Oral intake may be enhanced by teaching persons with
A-T how to drink, chew and swallow more safely. Treat-
ments for swallowing problems should be determined
following evaluation by an expert in the field of speech-
language pathology. Dieticians may help treat nutrition
problems by recommending dietary modifications, in-
cluding high calorie foods or food supplements. To de-
crease the duration of mealtimes, caregivers may need to
prepare and present foods or liquids to facilitate self-
feeding or feed the person with A-T. Liquids are often
easier to drink from covered containers with straws ver-
sus from open cups. It may be easier to finger feed than
use utensils.
A gastrostomy tube (G-tube or feeding tube) is recom-
mended when any of the following occur: a child cannot
eat enough to grow or a person of any age cannot eat
enough to maintain weight; aspiration is problematic;
mealtimes are stressful or too long, interfering with
other activities [161].
Feeding tubes can decrease the risk of aspiration by
enabling persons to avoid liquids or foods that are diffi-
cult to swallow. They also provide adequate calories
without the stress and time commitment of prolonged
meals. G-tubes do not prevent people from eating by
mouth. People who undergo gastric tube placement
should initially be re-fed very slowly to avoid aspiration
due to gastroesophageal reflux. Once a tube is in place,
the general goal should be to maintain weight at the 10-
25th percentile.
It has been demonstrated that, when placed at an early
age, G-tubes can be well tolerated. In addition, care-
givers reported significant improvements in mealtime
satisfaction and participation in daily activities following
G-tube placement [161].
Two recent studies by specialized A-T clinical centers
in Germany and Australia have demonstrated that the
extent of nutritional compromise in A-T likely exceeds
previous estimates. Both groups demonstrated that mal-
nutrition, as measured by decreased body cell mass
(BCM) is a significant problem in the majority of people
with A-T ([162, 163]).
Together, these studies emphasize the very critical
need for nutritional intervention in certain people with
A-T, including early and ongoing nutritional support
and education for families and caregivers.
Problems associated with the management of cancers
The special problems of managing cancer in the context
of A-T are sufficiently complicated that treatment should
be performed only in academic oncology centers and
after consultation with physicians who have specific ex-
pertise in A-T. For example, standard cancer treatment
regimens need to be modified to avoid the use of radi-
ation therapy and radiomimetic drugs, as these are par-
ticularly cytotoxic for people with A-T [164]. The use of
cyclophosphamide must be monitored very carefully be-
cause it has been associated with severe hemorrhage
from telangiectasia that develop in the bladder ([147]
and unpublished observations). Of note, even with treat-
ment modifications, for some individuals with A-T and
advanced stage cancers toxicity may still pose significant
problems [165].
There are two reports in the literature of successful
bone marrow transplants (BMTs) for the treatment of T-
ALL and non-Hodgkin lymphoma in individuals with A-
T [166, 167]; however, the use of BMT for the treatment
of hematopoietic malignancies associated with A-T is an
area of active discussion.
Eye and vision problems
Eye muscle surgery can correct the strabismus that is
common in people with A-T and help improve quality of
life. Drugs that may improve other eye abnormalities,
such as 4-amino pyridine for nystagmus and vestibular
deficits [168], have not been rigorously prescribed or
tested in patients with A-T.
Orthopedic problems
Early treatment of foot deformities may slow their pro-
gression. Bracing or surgical correction sometimes
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improves stability at the ankle sufficient to enable an in-
dividual to walk with support, or bear weight during
assisted standing transfers from one seat to another. Se-
vere scoliosis is relatively uncommon, but probably does
occur more often than in those without A-T. Spinal fu-
sion is only rarely indicated.
Education and socialization
Most children with A-T have difficulty in school because
of a delay in response time to visual, verbal or other cues,
dysarthria, oculomotor apraxia and impaired fine motor
control. Despite these problems, children with A-T often
enjoy school if proper accommodations to their disability
can be made. The decision about the need for special edu-
cation classes or extra help in regular classes is highly in-
fluenced by the local resources available. Decisions about
proper educational placement should be revisited as often
as circumstances warrant. Despite their many neurologic
impairments, most individuals with A-T are very socially
aware and socially skilled, and thus benefit from sustained
peer relationships developed at school. Some individuals
are able to function quite well despite their disabilities and
a few have graduated from college.
Many of the problems encountered will benefit from
special attention, as problems are often related more to
“input and output” issues than to intellectual impair-
ment. Problems with eye movement control make it dif-
ficult for people with A-T to read, yet most fully
understand the meaning and nuances of text that is read
to them. Delays in speech initiation and lack of facial ex-
pression make it seem that they do not know the an-
swers to questions. Reduction of the skilled effort
needed to answer questions, and an increase of the time
available to respond, is often rewarded by real accom-
plishment. It is important to recognize that intellectual
disability is not regularly a part of the clinical picture of
A-T although school performance may be suboptimal
because of the many difficulties in reading, writing, and
speech. Children with A-T are often very conscious of
their appearance, and strive to appear normal to their
peers and teachers.
Life within the ataxic body can be tiring. The enhanced
effort needed to maintain appearances and increased en-
ergy expended in abnormal tone and extra movements all
contribute to physical and mental fatigue. As a conse-
quence, for some a shortened school day yields real
benefits.
General recommendations for the education and
socialization of children with A-T are outlined in Table 10.
Prognosis
Historically, individuals with A-T succumbed to their
disease in childhood or the teenage years. However, the
average life expectancy for individuals with A-T has
improved, and continues to improve, with advances in
care. In 2006, the average life expectancy was reported to
be approximately 25 years [37]. The two most common
causes of death are chronic lung disease (about one-third
of cases) and cancer (about one-third of cases).
Unresolved questions
General
Many unresolved questions exist with regards to the
complexity and severity of A-T. For example, the effect
of environmental factors, disease modifier genes, epigen-
etics, telomere length, and the gut microbiome on the
presentation, severity and progression of the various
manifestations of A-T remains unknown. In addition,
each manifestation has its own unresolved questions and
unmet needs. These are described in brief below.
Table 10 General Recommendations for the Education and
Socialization of Children with A-T
• All children with A-T need special attention to the barriers they
experience in school. In the United States, this takes the form of a formal
IEP (Individualized Education Program).
• Children with A-T tend to be excellent problem solvers. Their involvement
in how to best perform tasks should be encouraged.
• Speech-language pathologists may facilitate communication skills that
enable persons with A-T to get their messages across (using key words
vs. complete sentences) and teach strategies to decrease frustration
associated with the increased time needed to respond to questions
(e.g., holding up a hand) and inform others about the need to allow
more time for responses. Traditional speech therapies that focus on the
production of specific sounds and strengthening of the lip and tongue
muscles are rarely helpful.
• Classroom aides may be appropriate, especially to help with scribing,
transportation throughout the school, mealtimes and toileting. The
impact of an aide on peer relationships should be monitored carefully.
• Physical therapy is useful to maintain strength and general
cardiovascular health. Horseback therapy and exercises in a swimming
pool are often well-tolerated and fun for people with A-T. However, no
amount of practice will slow the cerebellar degeneration or improve
neurologic function. Exercise to the point of exhaustion should be
avoided.
• Hearing is normal throughout life. Books on tape may be a useful
adjunct to traditional school materials.
• Early use of computers (preschool) with word completion software
should be encouraged.
• Practicing coordination (e.g. balance beam or cursive writing exercises)
is not helpful.
• Occupational therapy is helpful for managing daily living skills.
• Allow rest time, shortened days, reduced class schedule, reduced
homework, modified tests as necessary.
• Like all children, those with A-T need to have goals to experience the
satisfaction of making progress.
• Social interactions with peers are important, and should be taken
into consideration for class placement. For everyone, long-term peer
relationships can be one of the most rewarding parts of life; for those
with A-T establishing these connections in school years can be helpful.
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Neurology and neurodegeneration
Developmental and degenerative deficits Degenerative
neurological deficits are those that manifest loss of pre-
viously established abilities over time. The concept of
what comprises a “developmental defect” is somewhat
more complex, and can refer to either: 1) those deficits
that disrupt the process of development itself, or 2)
those that are present and fixed early, but the nature of
the deficit emerges as normal developmental processes
unveil the already limited capacity. The neurologic prob-
lems associated with A-T may well represent a mixture
of these different processes.
Neurodegeneration at the cellular level It is not yet
known why, despite the ubiquitous expression of ATM,
certain neurons in the brain, such as cerebellar PCs, are
so exquisitely sensitive to its loss while others appear
not to be affected. The specific vulnerability, and relative
health, of neurons despite the loss of ATM protein may
be cell autonomous, due to differing intrinsic properties
of the neurons themselves, or non-cell autonomous, i.e.
related to interactions in a circuit or relationships of se-
lected neurons to their supporting environment.
Neurodegeneration at the functional level Within the
brain as a whole, we do not understand the functional
specificity of the neurodegeneration associated with A-T.
For example: beyond the simple observation that ana-
tomic changes are concentrated in the cerebellum, the
circuits and extra-cerebellar brain regions involved in
the neurodegenerative process are not known. The in-
volvement of functions not traditionally ascribed to the
cerebellum has long been observed, but whether this is
itself true, or instead a function of the limited scope of
information about the appearance of neurologic disease
concentrated in the cerebellum, remains to be seen.
Longitudinal neuroimaging studies, starting at a young
age and early in the disease process and that track
neuropathological changes over time, are also lacking.
Contribution of the periphery The brain is supported
and affected by other organs of the body. As with other
neurodegenerative disorders, “peripheral” abnormalities,
such as malnutrition, oxidative stress, inflammation,
autoimmunity as well as aging and endocrine changes,
may contribute to the neurodegenerative process. Opti-
mal management of these other changes – many of
which are amenable to treatment – may help minimize
the neurologic manifestations.
Immunodeficiency
One of the most obvious unresolved questions with
regards to patients with classic A-T is why some suffer
from immunodeficiencies like hypogammopathies and
lymphopenia while others do not.
Additionally, a recent study of the incidence of cancers
in a national cohort of French patients with A-T found
low levels of IgA in those patients who developed
lymphoid cancers as compared to patients who devel-
oped carcinomas or those without cancers [48]. This ob-
servation raises the question as to whether low IgA
levels are a risk factor or biomarker for the development
of lymphoid malignancies in A-T.
Immunodeficiency, specifically low IgG and low IgA
levels in combination with elevated IgM levels, may
also be a risk factor for a worsening overall disease
course [169].
Pulmonology
There exist many gaps in our knowledge regarding pul-
monary disease in A-T. In general, there is a need for:
clinical methods to identify those at increased risk for
pulmonary decline and disease; optimal protocols for
treatment of lung disease; alternative lung imaging tech-
niques (MRI versus CT) for the routine monitoring of
pulmonary disease; and the banking of lung tissue from
patients with A-T and pulmonary disease. The contribu-
tion of inflammation to lung disease and the direct effect
of ATM loss on lung epithelium are currently areas of
active research. Unresolved questions related to recur-
rent sinopulmonary disease and bronchiectasis, ILD and
bulbar weakness have been previously reviewed [124].
With particular regard to neuromuscular weakness,
there is a need for cost/benefit assessment of exercises
or regimens that strengthen the upper body including:
postural intervention; weight lifting; respiratory therapy
including inspiratory and expiratory muscle training;
and Lee Silverman Voice Therapy.
Cancers
Cancer is not a uniform manifestation of A-T, therefore
the identification of biomarkers and risk factors for the
development of malignancies in A-T would be valuable.
A study in Atm deficient mice demonstrated relation-
ships between housing with sterile or non-sterile diet,
water and bedding, the intestinal microbiome and the
onset of lymphoma in these animals [170]. Since the in-
testinal microbiome has been shown to contribute to
basal levels of inflammation and oxidative stress, this
study adds to the growing body of evidence that malig-
nancy can be influenced by such factors.
The development of less toxic treatment regimens for
cancers that occur in the context of A-T is a critical
need. Although these cancers can be successfully treated,
consequences of therapy including late onset adverse
events often occur. Standard guidelines for patient as-
sessment before therapy and supportive care during and
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after therapy are also lacking. Although challenging, the
development of standard protocols for the treatment of
the most common type of cancers in A-T (e.g. diffuse
large B cell lymphoma) would be valuable.
There is also a need for centralized pathology review
and the routine genotyping and banking of tumor tissue
from patients. A paucity in the latter has hampered our
understanding of the biochemical pathways involved in
the development of cancers in the context of A-T and
consequently our ability to develop targeted therapies.
Conclusions
Since its formal designation as a disease entity in 1957, a
tremendous amount has been learned about the clinical
manifestations of A-T, and advances in clinical care have
significantly improved the average life span of individ-
uals suffering from this disease.
Clinical guidance document for A-T
In October 2014, a clinical guidance document on the
diagnosis and treatment of ataxia telangiectasia in chil-
dren was published by the UK A-T Society [88]. Written
by specialists at the pediatric A-T Specialist Center in
Nottingham, UK, the guidance is aimed at non-
specialists to encourage a consistent multidisciplinary
approach to treating A-T. In addition to the key clinical
areas of genetics, neurology, pulmonary care, immun-
ology and cancer, the document covers physical therapy,
dietary management and the implications of surgery in
people with A-T.
International A-T patient registries
The field of A-T clinical research would benefit greatly
from an international database for the storing and shar-
ing of de-identified patient demographic information
and clinical data. Ideally, such a database would house
information related to the different facets of A-T includ-
ing, but not limited to: immunology, genetics and gen-
omic data, neurology and neuroimaging, pulmonology,
cancer and growth and nutrition. Access to information
on this scale would greatly improve our understanding
of the natural history of A-T, facilitate retrospective as
well prospective clinical studies, and readily allow clini-
cians to select appropriate cohorts of individuals for
multi-site, therapeutic trials.
Global A-T family data platform
To address this need, and to make data about individuals
with A-T rapidly accessible to scientists and physicians
for analysis, the Global A-T Family Data Platform was
launched in July of 2016 [171]. Parents or guardians of
children with A-T, or individuals with A-T themselves,
share their medical information and have the option to
provide a sample of their or their child’s saliva for whole
genome sequencing. With advice from a Scientific and
Medical Advisory Board, a Family Oversight Committee
- including family members from 10 different countries -
oversees the mission and activities of the Platform.
International A-T registry
In parallel to the Platform, an international A-T patient
registry is being developed. Funded by a European Com-
mission Horizon 2020 grant and overseen by a scientific
board of clinical experts and patient representatives, the
registry will contain baseline and longitudinal data pro-
vided by clinicians and clinical centers who treat individ-
uals with A-T. The dataset will include the fields noted
above. The international A-T advocacy community is
taking steps to enable the linkage of data between the
two registries and potentially other databases holding in-
formation on people with A-T.
“ATM syndrome”
A 2015 historical review of A-T proposed “ATM Syn-
drome” as a new designation for A-T [172]. It remains
to be seen if this will become an active topic for discus-
sion amongst the international A-T clinical and advocacy
communities.
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